Kymera Therapeutics, Inc. (KYMR)
KYMR moved a median of -0.06% 30 minutes after news, and -0.05% by the close. How KYMR actually reacts to news — the realized, point-in-time move the market made, measured across 483 labeled events over the last three years with zero look-ahead.
KYMR’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.17% | 53% | 483 |
| 30-min | -0.06% | 48% | 483 |
| 60-min | +0.07% | 51% | 483 |
| to close | -0.05% | 49% | 482 |
| Middle 50% of KYMR reactions | -1.19% to +1.50% |
|---|---|
| Median reaction (30-min) | -0.06% |
| Measured reactions | 483 |
Half of all Kymera Therapeutics, Inc. news events land between -1.19% and +1.50% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How KYMR reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 26 | +0.05% | 50% | -0.11% |
| Analyst downgrades | 14 | +0.64% | 86% | +1.88% |
| Coverage initiations | 45 | +0.02% | 51% | +0.39% |
| Rating reiterations | 118 | -0.14% | 42% | -0.14% |
| Price-target raises | 29 | +0.15% | 62% | +0.02% |
| Price-target cuts | 10 | +0.18% | 50% | +0.29% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how KYMR ranks against every other measured name →
That’s how KYMR usually reacts — get an email when it moves on news →Email me when KYMR moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to KYMR's baseline. Nothing else.
Recent KYMR events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Kymera Therapeutics to Participate in Upcoming September Investor Conferences | Press release | GlobeNewswire | -0.01% | -1.14% | |
| Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses | Press release | GlobeNewswire | +0.77% | +1.82% | |
| Form 10-Q Kymera Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.67% | +0.59% | |
| Form 8-K Kymera Therapeutics, For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | +0.67% | +0.59% | |
| Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update | Press release | GlobeNewswire | +0.67% | +0.59% | |
| Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026 | Press release | GlobeNewswire | +0.49% | +0.24% | |
| Form 8-K Kymera Therapeutics, For: Jul 27 | SEC filing · Form 8-K | SEC EDGAR | -0.64% | -2.40% | |
| Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer | Press release | GlobeNewswire | -0.64% | -2.40% | |
| Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader | Press release | GlobeNewswire | +0.60% | +3.45% | |
| Form 8-K Kymera Therapeutics, For: Jun 25 | SEC filing · Form 8-K | SEC EDGAR | +12.08% | +7.04% | |
| Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026 | Press release | GlobeNewswire | +12.08% | +7.04% | |
| Form 8-K Kymera Therapeutics, For: Jun 24 | SEC filing · Form 8-K | SEC EDGAR | +12.08% | +7.04% | |
| Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors | Press release | GlobeNewswire | +12.08% | +7.04% | |
| Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting | Press release | GlobeNewswire | +0.97% | +4.45% | |
| Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration | Press release | GlobeNewswire | +0.59% | +2.71% | |
| Form 8-K Kymera Therapeutics, For: Jun 05 | SEC filing · Form 8-K | SEC EDGAR | +0.59% | +2.71% | |
| Kymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development Operations | Press release | GlobeNewswire | +0.59% | +2.71% | |
| Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses | Press release | GlobeNewswire | +0.71% | -1.04% | |
| Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference | Press release | GlobeNewswire | +0.52% | +1.36% | |
| Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses | Press release | GlobeNewswire | -0.67% | -2.06% | |
| Kymera Therapeutics to Participate in Upcoming May Investor Conferences | Press release | GlobeNewswire | -0.27% | +2.59% | |
| Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week | Press release | GlobeNewswire | +0.19% | -1.05% | |
| Form 10-Q Kymera Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.11% | -5.06% | |
| Form 8-K Kymera Therapeutics, For: Apr 30 | SEC filing · Form 8-K | SEC EDGAR | -1.11% | -5.06% | |
| Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update | Press release | GlobeNewswire | -1.11% | -5.06% | |
| Form ARS Kymera Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.11% | -5.06% | |
| Form DEF 14A Kymera Therapeutics, For: Jun 24 | SEC filing · Form DEF | SEC EDGAR | -1.11% | -5.06% | |
| Form DEFA14A Kymera Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -1.11% | -5.06% | |
| Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026 | Press release | GlobeNewswire | +0.94% | -1.91% | |
| Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma | Press release | GlobeNewswire | +0.76% | +4.01% | |
| Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate | Press release | GlobeNewswire | -0.27% | +1.29% | |
| Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting | Press release | GlobeNewswire | +2.55% | +0.95% | |
| Form 8-K Kymera Therapeutics, For: Mar 25 | SEC filing · Form 8-K | SEC EDGAR | +2.55% | +0.95% | |
| Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting | Press release | GlobeNewswire | +1.89% | -0.33% | |
| Form 10-K Kymera Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +5.92% | +10.50% | |
| Form 8-K Kymera Therapeutics, For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | +5.92% | +10.50% | |
| Form S-8 Kymera Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +5.92% | +10.50% | |
| Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update | Press release | GlobeNewswire | +5.92% | +10.50% | |
| Kymera Therapeutics to Participate in Upcoming March Investor Conferences | Press release | GlobeNewswire | -0.03% | +2.73% | |
| Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 | Press release | GlobeNewswire | -1.02% | +2.32% | |
| Kymera Therapeutics to Participate in Upcoming February Investor Conferences | Press release | GlobeNewswire | -0.54% | +0.22% | |
| Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader | Press release | GlobeNewswire | -1.69% | +3.81% | |
| Form 8-K Kymera Therapeutics, For: Jan 13 | SEC filing · Form 8-K | SEC EDGAR | -0.19% | +1.59% | |
| Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs | Press release | GlobeNewswire | -0.19% | +1.59% | |
| Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13 | Press release | GlobeNewswire | -0.64% | +3.96% | |
| Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares | Press release | GlobeNewswire | -0.50% | -0.46% | |
| Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis | Press release | GlobeNewswire | +0.31% | -3.23% | |
| Form 8-K Kymera Therapeutics, For: Dec 08 | SEC filing · Form 8-K | SEC EDGAR | +0.31% | -3.23% | |
| Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering | Press release | GlobeNewswire | +0.15% | -3.42% | |
| Form 8-K Kymera Therapeutics, For: Dec 08 | SEC filing · Form 8-K | SEC EDGAR | +5.97% | +5.75% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the KYMR section they belong to.
Where else KYMR is measured.
KYMR earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Kymera Therapeutics, Inc.'s median reaction calculated?
Every labeled KYMR news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 483 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of KYMR's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does KYMR's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.